Joseph Jankovic

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Medical management of levodopa-associated motor complications in patients with Parkinson's disease
    Joseph Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas 77030, USA
    CNS Drugs 21:677-92. 2007
  2. ncbi request reprint Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:193-7. 2007
  3. ncbi request reprint Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurosci Lett 430:18-22. 2008
  4. doi request reprint Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo
    Tianhong Pan
    Parkinson s Disease Research Laboratory, Baylor College of Medicine, 6501 Fannin Street, Houston, TX 77030, USA
    Brain Res 1222:222-9. 2008
  5. ncbi request reprint Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurosci Lett 419:104-7. 2007
  6. doi request reprint Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease
    Wenjie Xie
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neurochem 115:188-99. 2010
  7. ncbi request reprint Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, Tex 77030, USA
    Arch Neurol 63:273-7. 2006
  8. doi request reprint Analysis of CYP2D6 genotype and response to tetrabenazine
    Raja Mehanna
    Parkinson s Disease Center, Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 28:210-5. 2013
  9. doi request reprint Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration
    Wen Zhu
    Department of Neurology, NB 205, Baylor College of Medicine, Houston, TX 77030, USA
    Neurobiol Dis 37:307-13. 2010
  10. doi request reprint Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule
    M Zouhair Atassi
    Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, United States
    Immunobiology 217:17-27. 2012

Collaborators

Detail Information

Publications120 found, 100 shown here

  1. ncbi request reprint Medical management of levodopa-associated motor complications in patients with Parkinson's disease
    Joseph Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas 77030, USA
    CNS Drugs 21:677-92. 2007
    ....
  2. ncbi request reprint Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:193-7. 2007
    ..6%), and akathisia (7.6%). Comparison of log-likelihood ratios revealed that age was a reliable predictor of Parkinsonism (P < 0.0001). TBZ is a safe and effective drug for the long-term treatment of hyperkinetic movement disorders...
  3. ncbi request reprint Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurosci Lett 430:18-22. 2008
    ..The results may provide new insights into the cause and diagnosis of PD and have implications for genetic counseling...
  4. doi request reprint Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo
    Tianhong Pan
    Parkinson s Disease Research Laboratory, Baylor College of Medicine, 6501 Fannin Street, Houston, TX 77030, USA
    Brain Res 1222:222-9. 2008
    ..These findings suggest that reduction in Nurr1 expression increases susceptibility to DAergic neuron injury induced by UPS impairment...
  5. ncbi request reprint Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurosci Lett 419:104-7. 2007
    ..No P755L variant was found in our PD cohort. Therefore, we conclude that LRKK2 P755L variant is a rare cause of Caucasian PD and has no diagnostic utility in genetic testing of this population of patients...
  6. doi request reprint Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease
    Wenjie Xie
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neurochem 115:188-99. 2010
    ..Thus, this model recapitulates many neuropathological and behavioral features of PD, rendering it likely suitable for studying the mechanisms of nigral DA neuron degeneration and for testing the potential anti-PD medications...
  7. ncbi request reprint Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, Tex 77030, USA
    Arch Neurol 63:273-7. 2006
    ..Mutations in the parkin gene (PRKN) cause autosomal recessive early-onset Parkinson disease (EOPD)...
  8. doi request reprint Analysis of CYP2D6 genotype and response to tetrabenazine
    Raja Mehanna
    Parkinson s Disease Center, Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 28:210-5. 2013
    ....
  9. doi request reprint Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration
    Wen Zhu
    Department of Neurology, NB 205, Baylor College of Medicine, Houston, TX 77030, USA
    Neurobiol Dis 37:307-13. 2010
    ..These results suggest that H-ferritin exerts neuroprotection possibly by modulating iron homeostasis and restoring proteasome activity...
  10. doi request reprint Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule
    M Zouhair Atassi
    Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, United States
    Immunobiology 217:17-27. 2012
    ..With the previous localization of the antigenic regions on the BoNT/B H chain, the human Ab recognition of the entire BoNT/B molecule is presented and compared to the recognition of BoNT/A by human blocking Abs...
  11. doi request reprint Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease
    Joseph Ferrara
    Parkinson Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    J Neurol Neurosurg Psychiatry 81:315-9. 2010
    ..In this study, we evaluate the effect of STN DBS on quality of life using the QLS(M), a modular questionnaire in which satisfaction scores for each item are weighted in light of patient-rated importance...
  12. ncbi request reprint A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Arch Neurol 64:421-4. 2007
    ..Mutations in the parkin gene cause autosomal recessive early-onset Parkinson disease (EOPD). The A265G variant in the HS1 binding protein 3 gene (HS1BP3) is common in essential tremor (ET)...
  13. pmc Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation
    Amy E Williams
    Department of Neurology, The Parkinson s Disease and Movement Disorders Center, Baylor College of Medicine, 6501 Fannin, NB302 Houston, TX 77030, USA
    Parkinsonism Relat Disord 17:321-7. 2011
    ..Our results suggest that neuropsychological evaluations may identify possible mild cognitive changes following surgery...
  14. ncbi request reprint Basal ganglia neuronal discharge in primary and secondary dystonia
    Manjit K Sanghera
    Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA
    Adv Neurol 94:29-36. 2004
  15. pmc Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location
    Michele K York
    Department of Neurology, The Parkinson s Disease and Movement Disorders Clinic, Baylor College of Medicine, the Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, United States
    J Neurol Sci 287:159-71. 2009
    ..We hypothesized that differences in electrode position and surgical trajectory may lead to a differential neuropsychological outcome...
  16. ncbi request reprint Genetic analysis of the GABRA1 gene in patients with essential tremor
    Hao Deng
    Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, Houston, TX 77030, USA
    Neurosci Lett 401:16-9. 2006
    ..Since the 156T>C variant appears to be not pathogenically relevant, our results suggest that missense, nonsense or splice site mutation in the coding region of the GABRA1 gene is not a major genetic cause of ET in Caucasian subjects...
  17. doi request reprint Amplitude fluctuations in essential tremor
    Giovanni Mostile
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, The Smith Tower, Suite 1801, 6550 Fannin, Houston, TX 77030, USA
    Parkinsonism Relat Disord 18:859-63. 2012
    ..To assess temporal amplitude variability in patients with essential tremor (ET)...
  18. doi request reprint Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B
    Minako Oshima
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    J Neuroimmunol 240:121-8. 2011
    ..1/year) were associated with a significantly higher T-cell response to BoNT/A in CD. T cell responses to BoNT/A did not differ between CD patients who had clinically responsive and non-responsive status at the time of enrollment...
  19. doi request reprint Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment
    M Zouhair Atassi
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Mol Immunol 45:3878-88. 2008
    ..These regions afford candidates for epitope-specific manipulation of anti-toxin immune responses...
  20. doi request reprint Respiratory problems in neurologic movement disorders
    Raja Mehanna
    Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Parkinsonism Relat Disord 16:628-38. 2010
    ..The aim of this review is to draw attention to the respiratory problems that are sometimes associated with these various movement disorders...
  21. ncbi request reprint Age-dependent dopaminergic dysfunction in Nurr1 knockout mice
    Chuantao Jiang
    Parkinson Disease Research Laboratory, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Exp Neurol 191:154-62. 2005
    ....
  22. doi request reprint Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans
    Philip R Deitiker
    Department of Biochemistry, Baylor College of Medicine, Houston, TX 77030, USA
    Autoimmunity 44:167-76. 2011
    ..However, longer distance associations within an extended and conserved DQB1*0604 bearing haplotype leave a possibility that a locus proximal to DQB1 might be involved...
  23. doi request reprint Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement
    Tianhong Pan
    Parkinson Disease Research Laboratory, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Neurobiol Dis 32:16-25. 2008
    ....
  24. doi request reprint Transcription factor PITX3 gene in Parkinson's disease
    Weidong Le
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurobiol Aging 32:750-3. 2011
    ..Our findings indicate that PITX3 may play a role in the pathogenesis of PD...
  25. doi request reprint A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration
    Xu Ping Li
    Parkinson Disease Research Laboratory, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurosignals 20:223-36. 2012
    ..These findings provide insight into the mechanistic interplay between UPS impairment and iron misregulation and suggest that the disturbances in IRP2, TfR1 and H-Frt may contribute to DA neuron degeneration...
  26. doi request reprint Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial
    Joseph M Ferrara
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, USA
    J Neurol Sci 285:195-7. 2009
    ..Adverse events were similar in frequency to previously published studies of PGB, the most common being drowsiness and dizziness...
  27. ncbi request reprint Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators
    Wen Zhu
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    FASEB J 21:3835-44. 2007
    ..Furthermore, M30, a derivative of VK-28 and neuroprotective agent rasagiline, may serve as a better neuroprotective therapy for PD...
  28. ncbi request reprint Genetic analysis of LRRK2 mutations in patients with Parkinson disease
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    J Neurol Sci 251:102-6. 2006
    ..These finding may provide new insights into the cause and diagnosis of PD and have implications for genetic counseling...
  29. ncbi request reprint The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor
    Alan Diamond
    Department of Neurology, Baylor College of Medicine, United States
    J Neurol Sci 260:199-203. 2007
    ..9% (p=0.008) and upper extremity 92.5% (p=0.008) TRS subscore. Functional improvement was noted with pouring liquids. Our findings provide support that STN DBS is an effective treatment of tremor associated with PD...
  30. doi request reprint A study of chorea after tetrabenazine withdrawal in patients with Huntington disease
    Samuel Frank
    Department of Neurology, Boston University School of Medicine, Boston, MA, USA
    Clin Neuropharmacol 31:127-33. 2008
    ..To assess tetrabenazine (TBZ) efficacy by evaluating the change in Huntington disease-associated chorea resulting from TBZ treatment withdrawal...
  31. ncbi request reprint Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells
    Tianhong Pan
    Parkinson Disease Research Laboratory, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    FEBS Lett 579:6716-20. 2005
    ..Activation of p-Akt, p-Bcl-2, as well as p-Erk1/2 by VPA may be co-contributors to the protection...
  32. ncbi request reprint Distinguishing psychogenic and essential tremor
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, United States
    J Neurol Sci 263:94-9. 2007
    ..In conclusion, a history of tremor with sudden onset and spontaneous remissions along with distractibility and suggestibility on examination are good predictors of PT and help differentiate it from ET...
  33. doi request reprint Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders
    Mark Hallett
    The George Washington University School of Medicine and Health Sciences, Ross Hall, Department of Neurology, 2300 Eye Street, NW Suite 713W, Washington, DC 20037, USA
    Toxicon 67:94-114. 2013
    ..Further research is needed to address evidence gaps and to evaluate BoNT formulations where currently there is insufficient or conflicting clinical data...
  34. doi request reprint Bilateral pedunculopontine nuclei strokes presenting as freezing of gait
    Sheng Han Kuo
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 23:616-9. 2008
    ..We report a patient with bilateral PPN infarcts whose dominant clinical feature was freezing of gait, thus providing evidence that PPN is involved in human locomotion and that damage to the PPN may lead to abnormal gait...
  35. pmc Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions
    Hsien Yang Lee
    Department of Neurology, UCSF, San Francisco, CA 94158, USA
    Cell Rep 1:2-12. 2012
    ....
  36. doi request reprint Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations
    José Fidel Baizabal Carvallo
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Stereotact Funct Neurosurg 90:300-6. 2012
    ..Deep brain stimulation (DBS) has proven to be an effective treatment for Parkinson's disease (PD) and other movement disorders, but its usefulness is limited by complications related to the hardware...
  37. ncbi request reprint The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor
    Hao Deng
    Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurosci Lett 407:97-100. 2006
    ..No mutations were found in our ET cohort and, therefore, we conclude that LRKK2 I2012T, G2019S and I2020T variants are rare causes of Caucasian ET...
  38. ncbi request reprint Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis
    Nina Browner
    Department of Neurology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Mov Disord 21:1500-2. 2006
    ..We successfully treated her myoclonus with injections of botulinum toxin A into the left zygomaticus muscle...
  39. ncbi request reprint Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease
    Peter A LeWitt
    Department of Neurology, Wayne State University School of Medicine, and Henry Ford Hospital Franklin Pointe Medical Center, 26400 West 12 Mile Road, Southfield, MI 48034, USA
    Clin Neuropharmacol 30:256-65. 2007
    ....
  40. ncbi request reprint Minocycline in Huntington's disease: a pilot study
    Madhavi Thomas
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
    Mov Disord 19:692-5. 2004
    ..Minocycline was well tolerated during this study period and no serious adverse events were noted...
  41. doi request reprint Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
    ..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted...
  42. doi request reprint Applause sign in Parkinsonian disorders and Huntington's disease
    Laura J C Wu
    Parkinson s Disease Center, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 23:2307-11. 2008
    ..We concluded that the applause sign is highly specific for parkinsonian disorders but it is not a specific sign for PSP; it appears to be most sensitive for CBD...
  43. doi request reprint Motor overflow and mirror dystonia
    Oraporn Sitburana
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, The Smith Tower, Suite 1801, Houston, TX 77030, USA
    Parkinsonism Relat Disord 15:758-61. 2009
    ..In this study, the severity of dystonia was significantly correlated with motor overflow in multiple tasks...
  44. doi request reprint Genetic study of an American family with DYT3 dystonia (lubag)
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurosci Lett 448:180-3. 2008
    ..In contrast, TAF1 and CXCR3 gene expression in peripheral blood lymphocytes is not a suitable surrogate disease marker for DYT3...
  45. pmc Sensory aspects of movement disorders
    Neepa Patel
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Lancet Neurol 13:100-12. 2014
    ....
  46. doi request reprint Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study
    Lawrence W Elmer
    Department of Neurology, Parkinsons Disease and Movement Disorders Program, Center for Neurological Health, College of Medicine, University of Toledo, 3000 Arlington Avenue, MS 1195, Toledo, OH 43614 2598, USA
    Parkinsonism Relat Disord 18:488-93. 2012
    ..This prospective, open-label extension (SP702; NCT00594165) of a 6-month double-blind, randomized study investigated the long-term safety and tolerability of rotigotine transdermal system in early Parkinson's disease (PD)...
  47. ncbi request reprint Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism
    Hao Deng
    Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, Houston, TX 77030, USA
    Neurosci Lett 382:297-9. 2005
    ..Since none of these variations appear to be pathogenically relevant, our results suggest that mutation of PACRG plays little or no role in the development of EOP...
  48. doi request reprint Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders
    Joseph Ferrara
    Parkinson Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    J Neuropsychiatry Clin Neurosci 23:141-8. 2011
    ..Although the tingling sensation produced by TENS makes it poorly suited for a controlled clinical trial, the device has a favorable side-effect profile and is an acceptable palliative treatment for a subset of PMD patients...
  49. doi request reprint Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients
    Minako Oshima
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    J Neuroimmunol 237:66-72. 2011
    ..BoNT-treated patients gave significantly higher in vitro T-cell responses to TeNT than did the controls...
  50. doi request reprint A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mov Disord 23:2194-201. 2008
    ..We here describe the rationale for the study and baseline characteristics of the 1,176 patients who have been enrolled into the trial...
  51. doi request reprint Iron chelation and neuroprotection in neurodegenerative diseases
    Xuping Li
    Department of Neurology, Baylor College of Medicine, NB205, One Baylor Plaza, Houston, TX 77030, USA
    J Neural Transm (Vienna) 118:473-7. 2011
    ....
  52. doi request reprint Long-term deep brain stimulation for essential tremor: 12-year clinicopathologic follow-up
    Daniel J Dilorenzo
    Department of Neurosurgery, The Methodist Hospital, Houston, Texas, USA
    Mov Disord 25:232-8. 2010
    ..The case represents the longest reported follow-up with autopsy examination after DBS and confirmed histological changes associated with ET...
  53. doi request reprint Atomoxetine for freezing of gait in Parkinson disease
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, United States
    J Neurol Sci 284:177-8. 2009
    ..Further studies in a larger population of patients with FoG are needed to determine whether atomoxetine is a useful drug in the treatment of this, often disabling, feature of PD...
  54. doi request reprint Disease-oriented approach to botulinum toxin use
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Toxicon 54:614-23. 2009
    ....
  55. doi request reprint Relationship between various clinical outcome assessments in patients with blepharospasm
    Joseph Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 24:407-13. 2009
    ..Both, JRS and BSDI, can be used to reliably assess blepharospasm in treatment trials...
  56. pmc Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
    Rodger J Elble
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
    Mov Disord 25:1082-6. 2010
    ..We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment...
  57. doi request reprint Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
    William J Marks
    Department of Neurology, University of California San Francisco, San Francisco, CA, USA
    Lancet Neurol 9:1164-72. 2010
    ..We aimed to assess the safety and efficacy of AAV2-neurturin in a double-blind, phase 2 randomised trial...
  58. ncbi request reprint Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neurosurg 106:621-5. 2007
    ..The object of this study was to assess the long-term safety of deep brain stimulation (DBS) in a large population of patients with a variety of movement disorders...
  59. ncbi request reprint Genetics of essential tremor
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Brain 130:1456-64. 2007
    ..Further analyses of these genetic abnormalities may lead to the identification of causative mutations and a better understanding of the molecular mechanisms in this common movement disorder...
  60. ncbi request reprint Short-term effects of tetrabenazine on chorea associated with Huntington's disease
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:10-3. 2007
    ..2 hours to a maximum of 8.1 hours (mean = 5.4 +/- 1.3). No patient experienced an adverse event related to TBZ or its withdrawal. During short-term follow-up after a single dose, TBZ improves chorea for approximately 5 hours...
  61. ncbi request reprint An open-label pilot study of levetiracetam for essential tremor
    William G Ondo
    Baylor College of Medicine, Department of Neurology, Houston, Texas 77030, USA
    Clin Neuropharmacol 27:274-7. 2004
    ..Adverse events included dizziness (n=2), sedation (n=1), and nervousness (n=1). Levetiracetam was well tolerated but failed to improve tremor consistently in this small trial...
  62. ncbi request reprint A peptide-based immunoassay for antibodies against botulinum neurotoxin A
    M Zouhair Atassi
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    J Mol Recognit 20:15-21. 2007
    ....
  63. ncbi request reprint Essential tremor among children
    Joseph Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin St, Suite 1801, Houston, TX 77030, USA
    Pediatrics 114:1203-5. 2004
    ..To characterize the clinical and therapeutic aspects of essential tremor (ET) among children...
  64. ncbi request reprint Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Arch Neurol 64:676-82. 2007
    ..To assess the response to the rotigotine transdermal system (Neupro; Schwarz Pharma Ltd, Monheim, Germany), a nonergolinic dopamine agonist, in patients with early Parkinson disease...
  65. ncbi request reprint Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease
    Chuantao Jiang
    Parkinson Disease Research Lab, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Clin Neuropharmacol 27:63-73. 2004
    ....
  66. ncbi request reprint Glabellar and palmomental reflexes in Parkinsonian disorders
    Harris Brodsky
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurology 63:1096-8. 2004
    ....
  67. ncbi request reprint Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration
    Madhavi Thomas
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 19:36-42. 2004
    ..The phenotypic heterogeneity observed in our patients supports the notion of genetic heterogeneity in the HSS/NBIA syndrome...
  68. ncbi request reprint Long-term evaluation of deep brain stimulation of the thalamus
    Rajesh Pahwa
    Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    J Neurosurg 104:506-12. 2006
    ..The aim of this study was to evaluate the long-term safety and efficacy of DBS of the ventralis intermedius nucleus (VIM) of the thalamus for PD and ET...
  69. ncbi request reprint Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y
    Hao Deng
    Department of Neurology, Baylor College of Medicine, USA
    Biochem Biophys Res Commun 337:1133-8. 2005
    ..These findings support the hypothesis that PINK1 participates in the protection of dopaminergic neurons...
  70. ncbi request reprint Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease
    Ron Tintner
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, USA
    Arch Neurol 62:1290-5. 2005
    ..We also review evidence that the risk of this complication is substantially lower with the newer nonergot dopamine agonists...
  71. doi request reprint The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease
    Tianhong Pan
    Parkinson s Disease Research Laboratory, Baylor College of Medicine, Houston, TX 77030, USA
    Brain 131:1969-78. 2008
    ..In this review, we summarize the recent findings related to this topic and discuss the unique role of the ALP in this neurogenerative disorder and the putative therapeutic potential through ALP enhancement...
  72. ncbi request reprint Tetrabenazine in the treatment of hyperkinetic movement disorders
    Christopher Kenney
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX, USA
    Expert Rev Neurother 6:7-17. 2006
    ....
  73. ncbi request reprint Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A
    Behzod Z Dolimbek
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Mol Immunol 44:1029-41. 2007
    ..The molecular and clinical implications of these findings are discussed...
  74. ncbi request reprint Long-term botulinum toxin efficacy, safety, and immunogenicity
    Nicte I Mejia
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 20:592-7. 2005
    ..Except for 1 patient, the 4 Ab-positive and the 2 clinical nonresponders are being treated with BTX-B. This longest reported follow-up of BTX injections confirms the long-term efficacy and safety of this treatment...
  75. ncbi request reprint Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
    ..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
  76. ncbi request reprint Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, USA
    Expert Opin Pharmacother 8:1329-35. 2007
    ..Advantages over existing dopamine agonists include once-daily administration, absence of food interactions, maintenance of stable plasma levels and utility in patients with swallowing difficulties...
  77. doi request reprint Tourette's syndrome in adults
    Joseph Jankovic
    Parkinson Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 25:2171-5. 2010
    ..In addition, adults with TS are more likely to exhibit substance abuse and mood disorders compared with children with TS...
  78. ncbi request reprint Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Mov Disord 20:S11-6. 2005
    ..Recognition of the full spectrum of clinical phenomenology of levodopa-related motor complications is essential for their treatment and prevention...
  79. doi request reprint Treatment of hyperkinetic movement disorders
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
    Lancet Neurol 8:844-56. 2009
    ..Finally, success with surgical approaches, particularly deep brain stimulation in patients with Parkinson's disease who have levodopa-induced dyskinesias, has been extended to the treatment of many hyperkinetic movement disorders...
  80. pmc Genetic mouse models of essential tremor: are they essential?
    Joseph Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Invest 115:584-6. 2005
    ....
  81. ncbi request reprint Essential tremor: a heterogenous disorder
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 17:638-44. 2002
  82. ncbi request reprint Tetrabenazine treatment for Huntington's disease-associated chorea
    William G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Neuropharmacol 25:300-2. 2002
    ..TBZ was well tolerated and resulted in a significant improvement in modified AIMS scores in HD patients. These results support the use of TBZ for chorea in patients with HD...
  83. ncbi request reprint Mutations in NR4A2 associated with familial Parkinson disease
    Wei Dong LE
    Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
    Nat Genet 33:85-9. 2003
    ..Additionally, mutations in NR4A2 affect transcription of the gene encoding tyrosine hydroxylase. These data suggest that mutations in NR4A2 can cause dopaminergic dysfunction, associated with Parkinson disease...
  84. ncbi request reprint Levodopa strengths and weaknesses
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA
    Neurology 58:S19-32. 2002
    ..However, there is no support for levodopa-induced neurotoxicity from in vivo studies. This review discusses possible mechanisms of levodopa-related complications and therapeutic strategies for their prevention and management...
  85. ncbi request reprint Evidence-based review of patient-reported outcomes with botulinum toxin type A
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Neuropharmacol 27:234-44. 2004
    ..These studies provide evidence that BTX-A exerts meaningful benefits on the quality of life of patients treated with this biologic agent...
  86. ncbi request reprint Dopamine agonists in Parkinson's disease
    Ron Tintner
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin, 1801, Houston, Texas 77030, USA
    Expert Opin Investig Drugs 12:1803-20. 2003
    ..The adverse effects of DAs are similar to those experienced with LD, except that the ergot agents are associated with a small risk of tissue fibrosis not noted with the non-ergot DAs...
  87. ncbi request reprint Premonitory sensory phenomenon in Tourette's syndrome
    Carolyn Kwak
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 18:1530-3. 2003
    ..We conclude that premonitory sensations are an important aspect of motor tics and some patients perceive motor tics as a voluntary movement in response to an involuntary sensation...
  88. ncbi request reprint Treatment of cervical dystonia with botulinum toxin
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 19:S109-15. 2004
    ..Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long-term complications of CD, such as contractures and radiculopathy, have been largely eliminated...
  89. doi request reprint Preclinical biomarkers of Parkinson disease
    Yuncheng Wu
    Department of Neurology, Shanghai First People s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Arch Neurol 68:22-30. 2011
    ....
  90. doi request reprint Peripherally induced movement disorders
    Joseph Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA
    Neurol Clin 27:821-32, vii. 2009
    ..The pathophysiology of these disorders is reviewed...
  91. ncbi request reprint Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 94, One Gustave L Levy Place, New York, NY 10029, USA
    Mov Disord 20:S3-10. 2005
    ..If implemented early in the course of the disease, such treatments, if found effective, may not only alter the natural progression of the disease but may also delay or minimize motor and nonmotor complications associated with levodopa...
  92. ncbi request reprint Psychogenic tremor: long-term outcome
    Joseph Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    CNS Spectr 11:501-8. 2006
    ..Psychogenic movement disorders are increasingly encountered in specialized clinics, and represent approximately 15% of all patients evaluated in the Baylor College of Medicine Movement Disorders Clinic...
  93. ncbi request reprint An update on the treatment of Parkinson's disease
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, The Smith Tower, Suite 1801, 6550 Fannin, Houston, TX 77030, USA
    Mt Sinai J Med 73:682-9. 2006
    ....
  94. ncbi request reprint Exploring the relationship between essential tremor and Parkinson's disease
    Joohi Shahed
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, 6550 Fannin, Suite 1801, Houston, TX, USA
    Parkinsonism Relat Disord 13:67-76. 2007
    ..We examine here the evidence for and against an association between ET and PD, and critically review data supporting the notion that a subset of ET patients is predisposed to developing PD...
  95. ncbi request reprint Parkinson's disease and movement disorders: moving forward
    Joseph Jankovic
    Parkinson s Disease and Movement disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Lancet Neurol 7:9-11. 2008
  96. ncbi request reprint Subthalamic deep brain stimulation in patients with a previous pallidotomy
    William G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
    Mov Disord 21:1252-4. 2006
    ..This may be partially due to a selection bias, but it may also indicate that prior pallidotomy is a negative predictor of outcome of STN DBS and should be considered in patient selection...
  97. doi request reprint Movement disorders in musicians
    Joseph Jankovic
    Parkinson s Disease Center, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 23:1957-65. 2008
    ..To increase professional and public awareness and to facilitate the recognition of music-related neurological problems, we suggest that "medical problems of musicians" be included in curriculum of music schools and medical schools...
  98. ncbi request reprint Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease
    James K Sheffield
    Department of Neurology, Baylor College of Medicine, Parkinson s Disease Center and Movement Disorders Clinic, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Expert Rev Neurother 7:637-47. 2007
    ....
  99. ncbi request reprint Treatment of dystonia
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Lancet Neurol 5:864-72. 2006
    ....
  100. ncbi request reprint Searching for a relationship between manganese and welding and Parkinson's disease
    Joseph Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurology 64:2021-8. 2005
    ..The controversy has stimulated this review, the primary aim of which is to critically and objectively examine the evidence or lack of evidence for a relationship among welding, manganese, parkinsonism, and PD...